Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Vasc Health Risk Manag ; 18: 73-80, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35221690

RESUMO

Familial hypercholesterolemia (FH) is an autosomal dominant condition that leads to significantly elevated low-density lipoprotein cholesterol (LDL-C) levels and an elevated risk for cardiovascular disease. Mipomersen is an antisense oligonucleotide inhibitor targeted to apolipoprotein B-100 (apoB-100) mRNA that is administered via subcutaneous injection. Once administered, mipomersen causes selective degradation of the apoB-100 mRNA and inhibition of protein translation. This ultimately results in substantial reductions in LDL-C and other lipoprotein levels. Mipomersen is approved for the treatment of homozygous FH. In this review, we discuss its mechanism, current evidence, limitations of use including adverse events, and impact on health-related quality of life.


Assuntos
Anticolesterolemiantes , Hiperlipoproteinemia Tipo II , Anticolesterolemiantes/efeitos adversos , Humanos , Hiperlipoproteinemia Tipo II/diagnóstico , Hiperlipoproteinemia Tipo II/tratamento farmacológico , Hiperlipoproteinemia Tipo II/genética , Oligonucleotídeos , Medidas de Resultados Relatados pelo Paciente , Qualidade de Vida
2.
Rev. Hosp. Ital. B. Aires (2004) ; 35(3): 91-96, sept. 2015. ilus
Artigo em Espanhol | LILACS, UNISALUD, BINACIS | ID: biblio-1401177

RESUMO

En los últimos años han surgido algunas investigaciones y guías de práctica clínica relacionadas con el diagnóstico y tratamiento de las dislipidemias, que aportaron nuevos conocimientos (y controversias) sobre dicha problemática. En este resumen se describen, en primer lugar, las características de las "nuevas guías" norteamericanas para el manejo del colesterol publicadas a fines de 2013 y se comparan con las recomendaciones tradicionales. En segundo lugar, se analizan los últimos estudios que evaluaron el impacto cardiovascular de otros fármacos hipolipemiantes (ezetimibe y ácido nicotínico) en pacientes en prevención secundaria tratados con estatinas. Finalmente, se mencionan las nuevas drogas hipolipemiantes desarrolladas en los últimos años, como el lomitapide, el mipomersen y los inhibidores de la PCSK9, y se comentan el mecanismo de acción, su eficacia, sus efectos colaterales y los escenarios clínicos en donde podrían utilizarse. (AU)


In recent years, some research and clinical practice guidelines related to the diagnosis and treatment of dyslipidemia, which provided new knowledge (and controversy) about this problem have emerged. In this review, the characteristics of the American "new guidelines" for cholesterol management published by the end of 2013 are described, and they are compared with the traditional recommendations. In addition, recent studies assessing the cardiovascular impact of other lipid-lowering drugs (ezetimibe and nicotinic acid) in patients in secondary prevention treated with statins are analyzed. Finally, new hypolipidemic drugs developed in recent years are mentioned (lomitapide, mipomersen and PCSK9 inhibitors), discussing the mechanism of action, efficacy, side effects and clinical settings where they could be used. (AU)


Assuntos
Humanos , Benzimidazóis/uso terapêutico , Dislipidemias/tratamento farmacológico , Ezetimiba/uso terapêutico , Inibidores de PCSK9/uso terapêutico , Hipercolesterolemia/tratamento farmacológico , Hipolipemiantes/uso terapêutico , Niacina/uso terapêutico , Benzimidazóis/efeitos adversos , Benzimidazóis/farmacologia , Colesterol/sangue , Guias de Prática Clínica como Assunto , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Interações Medicamentosas , Dislipidemias/diagnóstico , Ezetimiba/efeitos adversos , Ezetimiba/farmacologia , Inibidores de PCSK9/efeitos adversos , Inibidores de PCSK9/farmacologia , Hipercolesterolemia/diagnóstico , Hipolipemiantes/efeitos adversos , Hipolipemiantes/farmacologia , Niacina/efeitos adversos , Niacina/farmacologia
3.
Rev. méd. Chile ; 142(7): 880-888, jul. 2014. tab
Artigo em Espanhol | LILACS | ID: lil-726179

RESUMO

Statins are the preferred treatment for hypercholesterolemia and several studies have demonstrated their long-term safety and efficacy in reducing cardiovascular morbidity and mortality. However, in some cases of severe hypercholesterolemia such as homozygous and heterozygous familial hypercholesterolemia or statin intolerant patients, statins can be less efficient. In recent years, new lipid-lowering agents with novel mechanisms of action have been developed to reduce LDL-cholesterol in patients with severe hypercholesterolemia, associated or not to conventional lipid-lowering therapy. These therapies include microsomal transfer protein inhibitor (Lomitapide), antisense oligonucleotide to Apo B100 (Mipomersen) and monoclonal antibodies against Proprotein convertase subtilisin/kexin type 9 (PCSK9). Different studies have shown the great effectiveness of these new therapies. Short-term studies confirmed their adequate security profile, especially in patients with homozygous familiar hypercholesterolemia or severe hypercholesterolemia. Some of these agents have been also tested in statin-intolerant patients. However, long-term studies are needed to evaluate their safety, effectiveness and impact on cardiovascular risk reduction.


Assuntos
Humanos , Anticolesterolemiantes/uso terapêutico , Hipercolesterolemia/tratamento farmacológico , Anticorpos Monoclonais/uso terapêutico , Benzimidazóis/uso terapêutico , Ensaios Clínicos como Assunto , Oligonucleotídeos/uso terapêutico , Pró-Proteína Convertases/uso terapêutico , Serina Endopeptidases/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA